Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Uso da somatotropina recombinante bovina em búfalas leiteiras I: produção e composição físico-química do leite

Objetivou-se avaliar a influência da somatotropina recombinante bovina (rbST) sobre a produção e os constituintes do leite de búfalas entre 63 e 154 dias em lactação. Foram utilizadas 22 búfalas, distribuídas em dois grupos experimentais: grupo rbST - aplicação de 500 mg de rbST a cada 14 dias; grupo controle - sem aplicação de rbST. A cada sete dias, foi aferida a produção de leite de todas as búfalas e coletada uma amostra para análise físico-química. As variáveis produtivas e as oriundas de análises laboratoriais foram avaliadas como medidas repetidas no tempo, utilizando-se o comando Repeated gerado pelo procedimento GLM do SAS. A média dos parâmetros estudados para os grupos rbST e controle foram, respectivamente: produção de leite - 6,54 vs. 6,68 kg; gordura - 6,31 vs. 6,34%; proteína 3,86 vs. 3,81%; lactose - 4,96 vs. 5,02%; sólidos totais - 16,05 vs. 16,03%; extrato seco desengordurado - 9,75 vs. 9,74%; contagem de células somáticas - 329,90 vs. 171,68 (x 1000/mL); e elecondutividade - 2,87 vs. 2,81mS/cm. A utilização de 500mg de rbST administrados quinzenalmente, entre 63 e 154 dias em lactação não alterou a produção de leite, a proporção dos constituintes e a CCS do leite de búfalas leiteiras.This study aimed to evaluate the effect of recombinant bovine somatotropin (rbST) on milk yield and the proportion of buffalo milk components during lactation. Twenty-two buffaloes randomly distributed in two experimental groups were used: Group rbST - application of 500mg rbST every 14 days, between 63 and 154 days in milk (DIM); Control Group - without treatment. Weekly, the milk yield of buffaloes was measured and a sample was collected for physicochemical analysis. The response variables were evaluated as repeated measures, using the Repeated procedure through the GLM procedure of SAS. Means of each variable after rbST and Control were: Milk yield - 6,54 vs. 6,68 kg; Fat - 6,31 vs. 6,34%; Protein - 3,86 vs. 3,81%; Lactose - 4,96 vs. 5,02%; Milk solids - 16,05 vs. 16,03%; Defatted dry matter - 9,75 vs. 9,74%; Somatic Cells Count - 329,90 vs. 171,68 (x 1000/mL); and electrical conductivity- 2,87 vs. 2,81mS/cm. The use of 500mg of rbST administered every two weeks, between 63 and 154 DIM did not affect milk yield, proportion of milk constituents and SCC of dairy buffaloes

Use of recombinant bovine somatotropin (rbST) in dairy buffaloes I: production and physicochemical composition of milk

<p></p><p>ABSTRACT This study aimed to evaluate the effect of recombinant bovine somatotropin (rbST) on milk yield and the proportion of buffalo milk components during lactation. Twenty-two buffaloes randomly distributed in two experimental groups were used: Group rbST - application of 500mg rbST every 14 days, between 63 and 154 days in milk (DIM); Control Group - without treatment. Weekly, the milk yield of buffaloes was measured and a sample was collected for physicochemical analysis. The response variables were evaluated as repeated measures, using the Repeated procedure through the GLM procedure of SAS. Means of each variable after rbST and Control were: Milk yield - 6,54 vs. 6,68 kg; Fat - 6,31 vs. 6,34%; Protein - 3,86 vs. 3,81%; Lactose - 4,96 vs. 5,02%; Milk solids - 16,05 vs. 16,03%; Defatted dry matter - 9,75 vs. 9,74%; Somatic Cells Count - 329,90 vs. 171,68 (x 1000/mL); and electrical conductivity- 2,87 vs. 2,81mS/cm. The use of 500mg of rbST administered every two weeks, between 63 and 154 DIM did not affect milk yield, proportion of milk constituents and SCC of dairy buffaloes.</p><p></p

Corantes comumente empregados na citogenética vegetal.

O emprego dos corantes, na citogenética vegetal, data de muitos anos, uma vez que as pesquisas nas áreas da citologia e histologia vêm sendo desenvolvidas constantemente desde os primeiros estudos celulares no século XIX. Inicialmente, eram extraídos de fontes vegetais ou animais, sendo atualmente produzidos sinteticamente em escala comercial. Os corantes são classificados em não fluorescentes e fluorescentes, conforme suas propriedades químicas e a escolha de uso é de acordo com o tipo de estrutura celular ou grupo celular a ser analisado. A diversidade de tipos e compostos químicos existentes nos diferentes corantes proporciona sua aplicação em estudos avançados na citogenética clássica e molecular. Uma revisão de suas propriedades químicas e emprego é apresentada para os corantes não fluorescentes orceína, hematoxilina, Giemsa, carmin; e para os fluorescentes 4',6-diamidino-2-fenilindol (DAPI), cromomicina A (CMA), fluoresceína e rodamina